CirCode Biomed Closes Multi-Million-Dollar Series A Financing

Shanghai, China – Aug.15^th, 2023, CirCode Biomed, an innovative biotechnology company focusing on the development of Circular RNA therapeutics, announced the completion of a multi-million-dollar Series A financing. The round was co-led by Johnson & Johnson Innovation – JJDC, Inc. and one other company, with participation from Superstring Capital and others.

CirCode

Founded 2 years ago, CirCode has achieved significant advancements in key technologies to pave the way for circular RNA drug development, and has multiple patent families covering this new technology and pending applications worldwide.

The funds raised in this round will be used to accelerate pipeline progress, facilitate the translation of circular RNA technology into therapies, and benefit a wide range of patients.